XBiotech Inc

4XB

Company Profile

  • Business description

    XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

  • Contact

    5217 Winnebago Lane
    AustinTX78744
    USA

    T: +1 512 386-2900

    E: [email protected]

    http://www.xbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    87

Stocks News & Analysis

stocks

An undervalued stock to buy that even Warren Buffett likes

Trading at an 18% discount, this wide-moat stock is a rare find.
stocks

ASX REIT downgraded following underwhelming exit

Discounted exit raises investor concerns.
stocks

Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,845.6051.40-0.58%
CAC 408,070.7310.70-0.13%
DAX 4025,384.48117.950.47%
Dow JONES (US)51,524.15174.170.34%
FTSE 10010,689.589.590.09%
HKSE24,510.09251.04-1.01%
NASDAQ26,995.5556.180.21%
Nikkei 22566,364.20850.211.30%
NZX 50 Index13,811.1113.72-0.10%
S&P 5007,718.9614.830.19%
S&P/ASX 2008,665.0037.00-0.43%
SSE Composite Index3,888.3748.15-1.22%

Market Movers